萬科(02202.HK)擬發20億人幣中期票據狀態顯示為「反饋中」募資全用於項目建設
據《央廣網》報道,全國銀行間市場交易商協會消息,萬科企業(02202.HK)(000002.SZ)關於發行2022年度第四期中期票據的註冊文件,涉資金額為20億元人民幣(下同)的中期票據項目狀態顯示為「反饋中」。
根據2022年度第四期中期票據募集說明書,發行人此次擬註冊中期票據20億元,首期發行20億元。其中,中期票據品種一期限為3+2年期,發行規模為10億元;品種二期限為5+2年期,發行規模同為10億元。兩品種間可進行回撥,回撥比例不受限制;且無信用增進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.